Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 3poly ICLC 1osimertinib 1fludarabine phosphate 1fludarabine 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1Taxes 1Risk Factors 1Pemetrexed 1Paclitaxel 1Nivolumab 1Injections, Subcutaneous 1High-Intensity Focused Ultrasound Ablation 1Gemcitabine 1Fluorouracil 1Dimethyl Sulfoxide 1Cyclophosphamide 1Cisplatin 1Ascorbic Acid 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Risk Factors × Dermatologic × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡